Kidney Cancer Research Summit

What Can Influence Immunotherapy Responses in Kidney Cancer?

August 5th 2025, 7:00pm

Video

TAMs may help predict response to PD-1 inhibitors in metastatic clear cell kidney cancer, Dr. Berkay Simsek reported at the 2025 Kidney Cancer Summit.

Key Immune Cells Linked to Better Kidney Cancer Outcomes

July 24th 2025, 4:00pm

Article

PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer; higher CD163-positive TAMs are linked to better outcomes.

Welireg Plus Cabometyx Shows Tumor Control in Kidney Cancer Trial

July 23rd 2025, 4:00pm

Article

Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated clear cell renal cell carcinoma.

In Vivo CAR T-Cell Approach May Lower Kidney Cancer Treatment Cost

July 23rd 2025, 1:00pm

Video

Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.

Clinical Trial Confirms Keytruda and Lenvima Benefit in Kidney Cancer

July 22nd 2025, 4:00pm

Article

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes.

How Q-TWiST Can Guide Kidney Cancer Treatment Choices

July 21st 2025, 8:00pm

Video

Q-TWiST may help patients with advanced kidney cancer and their doctors weigh treatment options by focusing on quality of life, not just disease control.

Metastasis-Directed Radiotherapy Shows Improved Kidney Cancer Outcomes

July 21st 2025, 7:00pm

Article

Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer.

Kidney Cancer Research Embraces Biology-Driven Precision Approach

July 21st 2025, 1:00pm

Video

Dr. Ari Hakimi highlighted how tumor profiling and molecular markers are expanding access to precision-based trials for kidney cancer.

Welireg Improves Quality-Adjusted Survival Time in Advanced RCC

July 20th 2025, 6:00pm

Article

Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.

Dual-Targeting CAR T Therapy Shows Potential in Advanced Kidney Cancer

July 20th 2025, 2:00pm

Article

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell carcinoma, a type of kidney cancer.